clinical trial · NCT04284761
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Prostate AdenocarcinomaLower Urinary Tract SymptomsBicalutamide implant
brief summary
Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether the Biolen is safe.
started
Oct 11, 2020
primary completion
May 3, 2023
completion
May 3, 2023
last updated
Jun 24, 2024
detailed description
This prospective, multi-center, single-arm feasibility study is planned to assess the safety and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate in patients presenting for treatment of prostate cancer. Study participants will have placement of the drug eluting Biolen and be followed through scheduled radical prostatectomy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol